Expertise in
16
conditions

Dr. Satish A. Shah

Hematology Oncology | Hematology | Oncology
Satish A Shah MD PC
20 Expedition Trail, 101 Gettysburg Cancer Center, 
Gettysburg, PA 
 (380.6 mi)
Clinical Trials:Currently Recruiting for 2 Trials
Expertise in
16
conditions
Satish A Shah MD PC
20 Expedition Trail, 101 Gettysburg Cancer Center, 
Gettysburg, PA 
 (380.6 mi)
OverviewInsuranceLocationsClinical Research

Overview

Satish Shah is a Hematologist Oncology specialist and a Hematologist in Gettysburg, Pennsylvania. Dr. Shah is highly rated in 16 conditions, according to our data. His top areas of expertise are Lung Cancer, Childhood Iron Deficiency Anemia, Chronic Familial Neutropenia, and Pleuropulmonary Blastoma.

His clinical research consists of co-authoring 3 peer reviewed articles and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in PA
Hospital Affiliations
Upmc Hanover
Gettysburg Hospital
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Cigna
  •  Humana

Locations

SATISH A SHAH MD PC
20 Expedition Trail, 101 Gettysburg Cancer Center, Gettysburg, PA 17325

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

QUILT-3.055: A Phase IIb, Multicohort, Open-Label Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors
QUILT-3.055: A Phase IIb, Multicohort, Open-Label Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors
Enrollment Status: Recruiting
Publish Date: January 29, 2025
Intervention Type: Drug
Study Drugs: N-803, Pembrolizumab, Nivolumab, Atezolizumab, Avelumab, Durvalumab, PD-L1 t-haNK
Study Phase: Phase 2
A Phase 1b/2 Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DISC-0974 in Participants with Myelofibrosis or Myelodysplastic Syndrome and Anemia
A Phase 1b/2 Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DISC-0974 in Participants with Myelofibrosis or Myelodysplastic Syndrome and Anemia
Enrollment Status: Recruiting
Publish Date: December 12, 2024
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
VISION: An International, Prospective, Open Label, Multicenter, Randomized Phase 3 Study of 177Lu-PSMA-617 in the Treatment of Patients With Progressive PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)
VISION: An International, Prospective, Open Label, Multicenter, Randomized Phase 3 Study of 177Lu-PSMA-617 in the Treatment of Patients With Progressive PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Enrollment Status: Completed
Publish Date: January 13, 2025
Intervention Type: Drug, Other
Study Drug: 177Lu-PSMA-617
Study Phase: Phase 3
PRESERVE 1: A Phase 3 Randomized, Double-blind Trial of Trilaciclib Versus Placebo in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer
PRESERVE 1: A Phase 3 Randomized, Double-blind Trial of Trilaciclib Versus Placebo in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer
Enrollment Status: Terminated
Publish Date: November 26, 2024
Intervention Type: Drug
Study Drug: Trilaciclib
Study Phase: Phase 3
A Phase 1 Open-label, Multicenter, Dose-ranging Study to Investigate Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1
A Phase 1 Open-label, Multicenter, Dose-ranging Study to Investigate Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1
Enrollment Status: Terminated
Publish Date: November 04, 2024
Intervention Type: Drug
Study Drug: MT-6402
Study Phase: Phase 1
Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-label, Active-controlled, Multicenter Trial
Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-label, Active-controlled, Multicenter Trial
Enrollment Status: Completed
Publish Date: October 30, 2024
Intervention Type: Drug
Study Drugs: Elacestrant, Standard of Care
Study Phase: Phase 3
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC762 in Subjects with Advanced or Metastatic Solid Tumors
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC762 in Subjects with Advanced or Metastatic Solid Tumors
Enrollment Status: Terminated
Publish Date: October 29, 2024
Intervention Type: Drug
Study Drug: NC762
Study Phase: Phase 1/Phase 2
QUILT 2.023: A Phase 3, Open-Label, 3-Cohort Randomized Study of N-803, in Combination With Current Standard of Care VS Standard of Care as First-Line Treatment for Patients With Advanced or Metastatic NSCLC.
QUILT 2.023: A Phase 3, Open-Label, 3-Cohort Randomized Study of N-803, in Combination With Current Standard of Care VS Standard of Care as First-Line Treatment for Patients With Advanced or Metastatic NSCLC.
Enrollment Status: Active_not_recruiting
Publish Date: August 14, 2024
Intervention Type: Drug
Study Drugs: N-803+Pembrolizumab, N-803+Carboplatin+Nab-paclitaxel+Pembrolizumab, N-803+Cisplatin or Carboplatin+Pembrolizumab+Pemetrexed, Pembrolizumab, Carboplatin+Nab-paclitaxel or Paclitaxel+Pembrolizumab, Cisplatin or Carboplatin+Pembrolizumab+Pemetrexed
Study Phase: Phase 3
An Open-Label, Randomized, Multicenter Study Evaluating the Activity of Lasofoxifene Relative to Fulvestrant for the Treatment of Pre- and Postmenopausal Women With Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
An Open-Label, Randomized, Multicenter Study Evaluating the Activity of Lasofoxifene Relative to Fulvestrant for the Treatment of Pre- and Postmenopausal Women With Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Enrollment Status: Active_not_recruiting
Publish Date: April 18, 2024
Intervention Type: Drug
Study Drugs: Lasofoxifene, Fulvestrant
Study Phase: Phase 2
An Observational Study Assessing the Clinical Effectiveness of VeriStrat and Validating Immunotherapy Tests in Subjects With Non-Small Cell Lung Cancer
An Observational Study Assessing the Clinical Effectiveness of VeriStrat and Validating Immunotherapy Tests in Subjects With Non-Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 07, 2024
A Disease Registry Encompassing the Care of Patients With Multiple Myeloma on Panobinostat (RECOMM)
A Disease Registry Encompassing the Care of Patients With Multiple Myeloma on Panobinostat (RECOMM)
Enrollment Status: Completed
Publish Date: June 15, 2023
Intervention Type: Drug
A Phase 2 Randomized, Double-blind, Clinical Trial of Trilaciclib Versus Placebo in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) Treated With Docetaxel in the 2nd/3rd Line Setting (PRESERVE 4)
A Phase 2 Randomized, Double-blind, Clinical Trial of Trilaciclib Versus Placebo in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) Treated With Docetaxel in the 2nd/3rd Line Setting (PRESERVE 4)
Enrollment Status: Terminated
Publish Date: April 14, 2023
Intervention Type: Drug
Study Drugs: Trilaciclib, Docetaxel
Study Phase: Phase 2
An Open-Label, Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant
An Open-Label, Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant
Enrollment Status: Approved_for_marketing
Publish Date: June 07, 2022
Intervention Type: Drug
An Open-label, Multi-center, Expanded Treatment Protocol (ETP) of Oral LDK378 in Adult Patients With Non-small Cell Lung Cancer (NSCLC) Characterized by ALK Positivity
An Open-label, Multi-center, Expanded Treatment Protocol (ETP) of Oral LDK378 in Adult Patients With Non-small Cell Lung Cancer (NSCLC) Characterized by ALK Positivity
Enrollment Status: No_longer_available
Publish Date: November 03, 2020
Intervention Type: Drug
View 12 Less Clinical Trials

3 Total Publications

A Phase I Study of Capivasertib in Combination With Abiraterone Acetate in Patients With Metastatic Castration-Resistant Prostate Cancer.
A Phase I Study of Capivasertib in Combination With Abiraterone Acetate in Patients With Metastatic Castration-Resistant Prostate Cancer.
Journal: Clinical genitourinary cancer
Published: August 31, 2022
Similar Doctors
Expertise in
16
conditions
Dr. Noah M. Hahn
Hematology Oncology | Oncology | Hematology
Expertise in
16
conditions
Dr. Noah M. Hahn
Hematology Oncology | Oncology | Hematology

Johns Hopkins University

600 N Wolf St, 
Baltimore, MD 
 (49.3 mi)
410-955-5000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Noah Hahn is a Hematologist Oncology specialist and an Oncologist in Baltimore, Maryland. Dr. Hahn is highly rated in 16 conditions, according to our data. His top areas of expertise are Bladder Cancer, Urothelial Cancer, Muscle Invasive Bladder Cancer, Nephrectomy, and Orchiectomy. Dr. Hahn is currently accepting new patients.

Expertise in
61
conditions
Dr. Michael B. Streiff
Hematology Oncology | Oncology | Hematology
Expertise in
61
conditions
Dr. Michael B. Streiff
Hematology Oncology | Oncology | Hematology

Johns Hopkins University

600 N Wolfe St, Blalock 266, 
Baltimore, MD 
 (49.3 mi)
410-502-4340
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Michael Streiff is a Hematologist Oncology specialist and an Oncologist in Baltimore, Maryland. Dr. Streiff is highly rated in 61 conditions, according to our data. His top areas of expertise are Venous Thromboembolism (VTE), Deep Vein Thrombosis, Pulmonary Embolism, Pancreaticoduodenectomy, and Bone Marrow Aspiration. Dr. Streiff is currently accepting new patients.

Expertise in
28
conditions
Dr. Robert A. Brodsky
Hematology | Oncology
Expertise in
28
conditions
Dr. Robert A. Brodsky
Hematology | Oncology

Johns Hopkins University

600 N Wolfe St, Blalock 266, 
Baltimore, MD 
 (49.3 mi)
410-502-4340
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Robert Brodsky is a Hematologist and an Oncologist in Baltimore, Maryland. Dr. Brodsky is highly rated in 28 conditions, according to our data. His top areas of expertise are Paroxysmal Nocturnal Hemoglobinuria (PNH), Paroxysmal Cold Hemoglobinuria, Anemia, Bone Marrow Transplant, and Splenectomy. Dr. Brodsky is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile